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Background: Letrozole, a non-steroidal aromatase inhibitor, prevents the body from producing its own estrogen.
The objectives of the present study were to test the hypotheses that letrozole treatment, initiated prior to selection
of the preovulatory dominant follicle, will induce the growth of more than one follicle to a pre-ovulatory size, and
will delay ovulation.
Methods: Post-pubertal beef heifers were given two luteolytic doses of PGF (12 h apart) and monitored by
ultrasonography for ovulation. Five to eight days later, ovarian follicular wave emergence was synchronized by
ultrasound-guided transvaginal follicular ablation (Day 0=wave emergence) and a luteolytic dose of PGF was given
60 and 72 h later. On Day 1, heifers were divided randomly into two groups (n=15/group) and an intravaginal
device containing 1 g of letrozole or a blank device (control) was inserted. The intravaginal devices were removed
on Day 7, or at the time of ovulation, whichever occurred first. Transrectal ultrasonography and blood sample
collection were performed daily from the day of ablation to 12 days after subsequent ovulation.
Results: The mean (+/−SEM) interval from device placement to ovulation was longer in letrozole-treated animals
compared to controls (6.1+/−0.25 vs 5.1+/−0.26 days, respectively; P<0.01). Single dominant follicles were present in
both groups. The day-to-day diameter profiles of the dominant follicles of the ovulatory wave were larger (P<0.05)
and the maximum diameters greater in letrozole-treated heifers (14.6+/−0.51 vs 12.4+/−0.53 mm, respectively;
P<0.01). The diameter profile of the corpus luteum (CL) that formed after treatment did not differ between groups;
however, plasma progesterone concentrations were higher (P<0.01) in heifers treated with letrozole. Estradiol
concentrations were reduced following letrozole treatment (P<0.05), although a preovulatory rise of estradiol
occurred in both groups.
Conclusions: Administration of letrozole with an intravaginal device during growth of the ovulatory follicle delayed
ovulation by 24 h and resulted in the formation of a CL that secreted higher levels of progesterone. A sustained-
release intravaginal device may be useful for the development of an aromatase inhibitor-based protocol to control
ovulation for herd synchronization and to enhance fertility by increasing circulating progesterone concentrations
during the first 7 days post-ovulation in cattle.
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Estrogen-based protocols, as a treatment for synchroniz-
ing ovulation in cattle, have modernized breeding prac-
tices and allowed producers to reliably control the
timing of ovulation, thus enabling efficient use of time,
labour and resources by allowing pre-scheduled insemin-
ation. Estradiol-based protocols also allow wider applica-
tion of superovulation and embryo transfer by enabling
effective synchronization of follicular wave emergence
[1-5]. However, increasing consumer sensitivity to the
possible deleterious effects of estrogens in food and in
the environment [6] has led to new regulations about
the use of estrogenic products in livestock. The
European Union has already banned the use of estro-
genic products in food producing animals [7-10]. In
United States [11] and Canada [12], estrogens cannot be
used for synchronization of estrus except by prescription
and custom-compounding. In 2007, New Zealand and
Australia banned use of estrogens in lactating dairy ani-
mals [10]. These policies have created a void in methods
to control reproductive function for breeding manage-
ment in cattle.
Non-steroidal aromatase inhibitors prevent the body
from producing its own estrogen. Letrozole, a non-
steroidal aromatase inhibitor, is used as an adjuvant
treatment for hormone-responsive breast cancer in post-
menopausal women [13] and has been used as a fertility
treatment for women undergoing assisted reproduction
[14]. The putative effect of letrozole on ovarian function
in women is through elevated follicle-stimulating hor-
mone (FSH) secretion by removal of the negative feed-
back of estradiol [14]. Tests of this hypothesis in a
bovine model, however, were not supportive of an effect
on FSH. In cattle, a single intravenous dose given on
Day 3 post-ovulation, or a 3-day regimen given on Days
1–3, 3–5 or 5–7 post-ovulation did not induce an eleva-
tion in circulating FSH concentration but did increase
mean plasma luteinizing hormone (LH) concentrations.
The effect on LH secretion resulted in a prolonged
period of dominance of the extant dominant follicle and
delayed emergence of the next follicular wave [15,16].
Further, a luteotrophic effect was inferred from the ob-
servation that heifers treated with letrozole for 3 days
had larger corpora lutea following treatment. Similar re-
sults were observed when letrozole was prepared in an
oil-based vehicle and administered intramuscularly [17].
To date, studies on the effects of letrozole on ovarian
function in cattle have been focused on non-ovulatory
follicular waves [15,16]. The present study was designed
to determine the effect of an extended period of treat-
ment with letrozole on the pre-ovulatory follicle in cat-
tle. We hypothesized that letrozole treatment initiated
before selection of the dominant ovulatory follicle and
extended over the follicle growing phase will induce thedevelopment of more than one follicle to a preovulatory
size, and delay ovulation. Additionally, we hypothesized
that the CL resulting from ovulations after letrozole
treatment will be larger and secrete more progesterone
than those from control heifers.
Methods
Cattle
Hereford-cross beef heifers (n=30), 15 to 20 months of
age and weighing between 235 and 405 kg (average
336 kg), were chosen from a herd of 51 heifers
maintained in outdoor pens at the University of Sas-
katchewan Goodale Research Farm (52° North and 106°
West). Heifers were fed alfalfa/grass hay and concentrate
to gain approximately 1.3 Kg per day and had water ad
libitum during the experimental period from October to
December. Heifers were initially examined by transrectal
ultrasonography (MyLab5 VET, Canadian Veterinary
Imaging, Georgetown, Ontario Canada) to detect the
presence of a CL (i.e., confirm post-pubertal status; [18].
Animal procedures were performed in accordance with
the Canadian Council on Animal Care and were ap-
proved by University of Saskatchewan Protocol Review
Committee.
Treatments and examinations
Heifers in which a CL was detected were given two
luteolytic doses of PGF (12 h apart) and monitored by
ultrasonography for ovulation. Five to eight days later,
the two largest ovarian follicles were ablated by
transvaginal ultrasound-guided follicular aspiration to
synchronize follicular wave emergence which was
expected to occur 1 to 1.5 days later [19,20]. Prostaglan-
din (500 μg cloprostenol, Estrumate, Schering-Plough
Animal Health, Pointe-Claire, QC, Canada) was given
intramuscularly at 60 and 72 h after follicular ablation to
induce regression of the CL and shift from a non-
ovulatory to an ovulatory follicular wave [21]. At the
time of follicular wave emergence (Day 0; i.e., 1.5 days
after follicle ablation), heifers were assigned randomly to
two groups and given an intravaginal device containing
1 g of letrozole (letrozole group, n=15) or a placebo
(letrozole-free) intravaginal device (control group, n=15).
Devices were inserted on Day 1 and were kept in place
until Day 7 or until ovulation was detected, which ever
occurred first.
Intravaginal devices were prepared using a Cue-Mate
spine (Bioniche Animal Health, Bellville, ON, Canada) as-
sembled with two blank (progesterone-free) silicone pods
that were coated with a gel-based vehicle containing
letrozole or vehicle only (control). The vehicle contained
the following (all ingredients % w/w): letrozole 10%, gelatin
20% (Gelatin type B, Fisher Scientific, Pittsburgh, PA,
USA), polymer 65% (prepared by mixing distilled water
Yapura et al. Reproductive Biology and Endocrinology 2013, 11:97 Page 3 of 8
http://www.rbej.com/content/11/1/9768%, Poloxamer 188 12% and Poloxamer 407 20%, both
from Spectrum Chemical, New Brunswick, NJ, USA) and
distilled water 5%.
Ovarian ultrasonography
The observations from ultrasound examinations were
recorded on a sketch sheet in which each ovary and its
structures (CL and follicles ≥ 4 mm in diameter) were
represented by size and location [22]. Ovulation was de-
fined as the disappearance of any follicle ≥8 mm be-
tween two consecutive daily examinations and was
confirmed by the subsequent development of a CL [18].
Follicular wave emergence was defined as occurring 1.5
days after follicular ablation [19]. The dominant follicle
of a wave was defined as the largest antral follicle of that
wave [23].
Collection of blood samples
Blood samples were collected by coccygeal venipuncture
into 10 mL heparinized vacuum tubes (Becton Dickinson
Vacutainer Systems, Franklin Lakes, NJ, USA). Samples
were collected daily from pre-treatment follicular wave
emergence (Day 0) to 12 days after the subsequent ovula-
tion. In a subset of letrozole-treated animals (n=4), fre-
quent blood samples were collected using an in-dwelling
jugular catheter, as previously described [24], at the time
of catheter placement and 0, 10, 20, 30 min, 1, 1.5, 2, 3,
4, 6, 8, 12 and 24 h after treatment for measurement of
plasma letrozole concentration. Blood samples were
centrifuged at 1500 × g for 20 min and plasma was sepa-
rated and stored in plastic tubes at −20°C.
Hormone assays
Plasma LH concentrations were determined in duplicate
using a double-antibody radioimmunoassay (NIDDK-
bLH4) [25,26]. The minimum and maximum values
along the standard curve were 0.06 and 8 ng/mL, re-
spectively. All samples were analyzed in a single assay;
the intra-assay coefficient of variation was 11.4% for low
reference samples (mean, 0.9 ng/mL) and 12.2% for high
reference samples (mean, 2.1 ng/mL).
Plasma FSH concentrations were determined in dupli-
cate using a double-antibody radioimmunoassay using
NIDDK-anti-oFSH-1 primary antibody and expressed as
USDA bovine FSH-Il units [25,26]. The minimum and
maximum values along the standard curve were 0.12
and 16 ng/mL, respectively. All samples were analyzed
in a single assay; the intra-assay coefficients of variation
were 7.9 and 6.5%, for low (mean, 2.4 ng/mL) and high
reference samples (mean 4.9 ng/mL), respectively.
Plasma concentrations of estradiol were determined
using a commercial radioimmunoassay kit (Double Anti-
body Estradiol; Diagnostic Products Corp., Los Angeles,
CA, USA). The procedure was carried out at theDepartment of Animal Health and Biomedical Sciences,
University of Wisconsin–Madison, as previously de-
scribed [27,28], with the following modifications: Stan-
dards (0.78–100 pg/mL) were prepared in steroid-free
(charcoal-treated) bovine plasma. The standards (250 μL
in duplicate) and plasma samples (500 μL in duplicate)
were extracted with 3 mL of diethyl ether, frozen in a
dry-ice/methanol bath, decanted into assay tubes, and
dried overnight under a fume hood. The dried samples
and standards were re-suspended with 100 μL of assay
buffer (0.1% gelatin in PBS). The intra- and inter-assay
coefficients of variation were 10.5 and 10.6% for high
reference samples (mean 11.1 pg/mL), and 14.8 and
12.3% for low reference samples (mean 2.6 pg/mL), re-
spectively. The sensitivity of the assay was 0.1 pg/mL.
Plasma progesterone concentrations were determined in
duplicate using a commercial solid-phase radioimmuno-
assay kit (Coat-A-Count; Diagnostic Products Corporation,
Los Angeles, CA, USA). The range of the standard curve
was 0.1 to 40.0 ng/mL. All samples were analyzed in a sin-
gle assay; the intra-assay coefficients of variation were 9.7%
and 5.8 % for low- (mean, 1.7 ng/mL) and high-reference
samples (mean, 18.7 ng/mL), respectively.
Letrozole concentrations
Plasma letrozole concentrations were quantified using
liquid chromatography tandem mass spectrometry
(LCMS/MS), as described [16]. Briefly, letrozole was
extracted from 250 mL plasma with 250 mL of 0.1M
ammonium acetate followed by the addition of 5 mL
methyl t-butyl ether (MTBE) and vortexed for 15 s. The
organic layer was removed and transferred to a fresh
15 mL plastic tube and dried by gentle nitrogen gas flow.
The dried extract was reconstituted in 1 mL of 100%
ethanol. Separation was accomplished by HPLC (Agilent
1200; Agilent, Santa Clara, CA, USA) fitted with an ana-
lytical column (50 × 2.1 mm, 3 mm particle size; Betasil
C18; Thermo Scientific, Waltham, MA, USA) operated
at 35°C. Mass spectra were collected using a tandem
mass spectrometer (SCIEX 3000; Applied Bioscience,
Foster City, CA, USA) fitted with an electrospray ionisa-
tion source, operated in the negative ionisation mode.
Quantification was performed using Analyst 1.4.1 soft-
ware provided by SCIEX (Applied Bioscience). The mini-
mum and maximum values along the standard curve
were 0.25 and 500 ng/mL, respectively. The limit of
quantification used in this method was 0.25 ng/mL and
the mean recovery was 70%.
The following pharmacokinetic parameters were deter-
mined: Cmax (maximum observed plasma concentration
of letrozole), tmax (time to reach Cmax), t1/2 (terminal
elimination half-life), AUC (area under the plasma
letrozole concentration-time curve from zero to infinity


























Days from wave emergence 
Control Letrozole
Treatment    0.05 
Day <.0001 
Treat*Day    0.85 
Figure 1 Dominant follicle diameter profiles (mean±SEM). Heifers
were treated with a blank (control, n=15) or a letrozole-containing
intravaginal device (letrozole, n=15). Devices were inserted on Day 1,
indicated by the arrow (Day 0 = wave emergence).
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was analyzed by non-compartmental techniques using a
computer modeling program (WinNonLin Standard Edi-
tion Version 2.1, Pharsight Corporation, Mountain View,
CA, USA). Peak letrozole concentration in plasma
(Cmax) and time to peak letrozole concentration (tmax)
were determined using observed values. The apparent
terminal rate constant (λ) was determined by linear re-
gression of the last 6–8 points on the terminal phase of
the logarithmic plasma concentration vs time curve. The
area under the C–t curve until the final plasma sample
(AUClast) was determined using the linear trapezoidal
rule. The total area under the curve extrapolated to in-
finity (AUC0-∞) was calculated by adding the Clast obs/λ +
AUClast. The terminal half-life (T1/2λ) was calculated as
ln2 ⁄λ. The mean residence time (MRT) was calculated as
the area under the moment curve extrapolated to infin-
ity (AUMC0-∞) ⁄AUC0-∞. Systemic clearance (ClS) was
determined using the dose divided by AUC0-inf. The ap-
parent volume of distribution (Vλ/f ) was calculated by
clearance divided by λ. Absolute bioavailability was cal-
culated by comparing letrozole AUClast obtained using
intravaginal devices to the AUClast obtained after a single
iv injection of letrozole (unpublished data), corrected by
dose (Bioavailability = (AUClast intravag/Doseintravag)/
(AUClast iv/Doseiv) × 100).22
24 Control LetrozoleStatistical analyses
Statistical analyses were done using the Statistical Analysis
System software package (SAS Learning Edition 9.1, 2006;
SAS Institute Inc., Cary, NC, USA). Time-series data (hor-
mone concentrations, follicle and CL diameter profiles)
were analyzed by repeated measures using the PROC
MIXED procedure. The main effects were treatment
(letrozole and control), time, and their interactions (noted
in figures as treatment, day and treat*day, respectively).
Single-point measurements (dominant follicle diameter at
device placement, maximum diameter of extant dominant
follicle, intervals from ablation to wave emergence, and
from device placement to ovulation) were analyzed by
t-tests. Individual time point comparisons betweenTable 1 Effects of a letrozole-containing intravaginal
device on ovarian function in heifers (mean±SEM)













3.9±0.47 4.2±0.46 0.68treatment groups were performed using least significant
difference test. Significance was defined as P ≤ 0.05.
Results
The diameter of the dominant follicle at the time of
intravaginal device placement on Day 1 (Day 0 = wave
emergence) did not differ between groups (Table 1). The
day-to-day diameter profile of the dominant follicle during
treatment and the maximum diameter of the ovulatory fol-
licle were larger in the letrozole-treated group (P=0.05 and
P=0.01; respectively (Figure 1; Table 1; respectively). The
interval from device placement to ovulation was longer in
heifers treated with letrozole than in controls (P=0.01,
Table 1). Single ovulation occurred in all heifers, regardless
of treatment.
Corpus luteum diameter profiles were not different be-
tween letrozole and control groups (P=0.82, Figure 2).
However, progesterone concentrations were higher during
the observational period (first 12 days post-ovulation) in
the letrozole-treated heifers compared to control heifers
(P=0.01, Figure 3).
Plasma estradiol concentrations were lower in the



















Days from post-letrozole treatment ovulation 
Treatment   0.82 
Day <.001 
Treat*Day   0.47 
Figure 2 Corpus luteum diameter profiles (mean±SEM)
following post-treatment ovulation. Heifers were treated with a


























Days from post-letrozole treatment ovulation 
Control Letrozole
Treatment    0.01 
Day  <.001 
Treat*Day    0.15 
Figure 3 Plasma progesterone concentrations (mean±SEM)
following post-treatment ovulation. Heifers were treated with a
























Days from wave emergence 
Control Letrozole
Treatment   0.10 
Day <.001 
Treat*Day   0.81 
Figure 5 Plasma FSH concentrations (mean±SEM). Heifers were
treated with a blank (control, n=15) or a letrozole-containing
intravaginal device (letrozole, n=15). Devices were given on Day 1 of
the ovulatory wave (Day 0 = wave emergence).
Yapura et al. Reproductive Biology and Endocrinology 2013, 11:97 Page 5 of 8
http://www.rbej.com/content/11/1/97(P=0.04, Figure 4). Treatment with letrozole did not pre-
vent a pre-ovulatory rise in estradiol but the rise was de-
layed in the letrozole group (Figure 4).
There was a tendency for lower plasma FSH concentra-
tions in the letrozole group compared to the control group
(P = 0.1; Figure 5). Mean plasma LH concentrations did
not differ between groups (P = 0.61; Figure 6).
Plasma letrozole concentrations are shown in Figure 7.
The half-life of letrozole in plasma was 33.3±4.56 h. Max-
imal concentrations in plasma (Cmax 31.7±1.65 ng/mL) oc-
curred at 24 h post-device insertion (Table 2). Additional
letrozole pharmacokinetic parameters are summarized in
Table 2.
Discussion
Previous studies of the effects of letrozole on ovarian func-
tion in cattle were focused on the non-ovulatory portion of
the estrous cycle in cattle [15-17]; hence, the effect of
letrozole treatment on pre-ovulatory follicles was the sub-
ject of the present study. Letrozole treatment during the


























Days from wave emergence 
Control Letrozole
Treatment   0.04 
Day <.001 
Treat*Day   0.56 
Figure 4 Plasma estradiol concentrations (mean±SEM). Heifers were
treated with a blank (control, n=15) or a letrozole-containing intravaginal
device (letrozole, n=15). Devices were given on Day 1 of the ovulatory
wave (indicated by the arrow; Day 0 = wave emergence).of the ovulatory follicle. This observation is consistent with
the results of previous studies in which larger dominant fol-
licles were observed when letrozole treatment was adminis-
tered during non-ovulatory follicular waves [15-17]. The
hypothesis that letrozole treatment initiated prior to the on-
set dominant follicle selection would result in multiple ovu-
latory follicle development [15] was not supported by the
results of the present study; single ovulations were detected
in both groups. However, ovulation was delayed by 24 h in
the letrozole-treated group. The larger ovulatory follicle
diameter observed in the letrozole-treated heifers may have
been affected by the length of the growing phase of these
follicles due to delayed ovulation. However, ovulatory dom-
inant follicle diameters in the letrozole-treated group were
already larger than the control group when compared 5
days after initiation of treatment (Day 6 post-wave emer-
gence). The stimulus driving the accentuated follicular
growth is unclear. However, daily sampling has limitations
when attempting to interpret gonadotropin concentrations


























Days from wave emergence 
Control Letrozole
Treatment   0.61 
Day <.001 
Treat*Day   0.15 
Figure 6 Plasma LH concentrations (mean±SEM). Heifers were
treated with a blank (control, n=15) or a letrozole-containing intravaginal
device (letrozole, n=15). Devices were given on Day 1 of the ovulatory


























Time from device insertion 
Figure 7 Plasma letrozole concentration (mean±SEM). Heifers (n=4) were given an intravaginal letrozole-releasing device for 6 days. *Between
indicated time points, values differed (P≤0.05).
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using more frequent sampling.
Estradiol concentrations were reduced following treat-
ment with letrozole-impregnated intravaginal devices,
and the preovulatory rise in estradiol concentrations oc-
curred 24 h later than in the control group. However,
the follicles maintained ovulatory capability. We infer
that the delay in estradiol rise observed in the letrozole-
treated group is responsible for the delay in ovulation in
this group.
In the present study, a letrozole-impregnated intravaginal
device was used to provide extended estradiol suppression
during the ovulatory wave. The intravaginal route of admin-
istration provides the advantage of reducing animal hand-
ling and distress caused by daily injections [29]. The
duration of estradiol inhibition was influenced by the phar-
macokinetic characteristics of the intravaginal device, and
accounts for the occurrence and timing of the estradiol
rise observed in the letrozole-treated group. The half-life
of letrozole observed following administration via an
intravaginal device (33 h) corresponded to that reported
previously after single intravenous administration in beef
heifers (unpublished data). Hence, the profile of letrozole
concentration over time obtained in the present study wasTable 2 Pharmacokinetics of a letrozole-containing intravagin
Parameter Heifer 1 Hei
Maximal concentration (Cmax) (ng/mL) 32.4 35
Half-life (T1/2) (hours) 35.1 20
Area under the curve (AUClast) (hours x ng/mL) 3538.1 269
Volume of distribution (Vz/f) (L/kg) 6.2 4
Systemic clearance (ClS) (L/hour/kg) 0.1 0
Mean residence time (MRT) (hours) 71.5 56
Bioavailabilityaffected primarily by the absorption characteristics of the
formulation used in the intravaginal devices. Based on the
plasma letrozole concentration profile, the intravaginal de-
vices released letrozole for only 24 h post-insertion, and
elimination and plasma clearance took place thereafter.
Therefore, letrozole concentrations may have dropped
below a critical level relatively rapidly, allowing for the
pre-ovulatory estradiol rise to occur after only a 24 h
delay. Bioavailability has been defined as the amount of a
drug given by any route, other than intravenously, that
reaches general circulation and is available at the site of
action [30]. The low bioavailability observed with the
intravaginal devices (16%) may be explained in part by the
melting point of the gel-vehicle used. This gel-based
vehicle is commonly used for intravaginal suppositories
for women, in which body temperature is lower than that
of cattle (37° vs 39°C) [31,32]. Rapid liquefaction of the
letrozole-containing gel resulted in loss of the preparation
through the vulvar opening during micturition, defecation,
or ultrasound examinations (the latter was observed by
the author).
Letrozole treatment during the growing phase of the
ovulatory follicle resulted in the ovulation of a larger fol-
licle. Although larger follicles did not result in larger CL,al device in heifers
fer 2 Heifer 3 Heifer 4 Mean SEM
.3 27.3 31.7 31.7 1.65
.4 41.9 35.7 33.3 4.56
7.7 2583.1 1698.0 2629.2 376.39
.9 9.9 13.2 8.5 1.87
.2 0.2 0.3 0.2 0.03
.2 65.5 48.7 60.5 5.03
16%
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over the first 12 days post-ovulation in the letrozole-
treated group. Preovulatory letrozole treatment may
have affected the number or proportion of large luteal
cells (granulosa cell origin) and small luteal cell (thecal
cell origin) contained within the CL [33], resulting in an
increase in progesterone production per CL volume.
Small and large luteal cells are present in the bovine CL
in a ratio of 7.6:1 [34]. Small luteal cells respond directly
to LH stimulus to secrete progesterone [35,36], while
large luteal cells appear to be responsible for sustained
secretion of progesterone in the absence of a stimulus
[36]. Treatment with letrozole may have resulted in an
increase in luteal cell numbers or an alteration in the
proportion of small and large luteal cells within the CL
and an increase in progesterone-producing capability
per CL volume. In this regard, treatment of cows with
equine chorionic gonadotropin resulted in increased
density and number of large luteal cells which increased
the capacity of the CL to produce progesterone [37]. Al-
though we were unable to document the effect of
letrozole treatment on gonadotropin secretion in the
present study, previous studies have shown an increase
in gonadotropin secretion after single or 3-day letrozole
regimen [15,38,39].
In summary, letrozole treatment during the ovulatory fol-
licle wave resulted in more rapidly growing dominant folli-
cles and a larger ovulatory follicles, delayed ovulation (by
24 h) of a single follicle and formation of a CL that secreted
higher levels of progesterone. The effects of treatment on
gonadotropin concentrations are inconclusive, possibly due
to inadequate sampling frequency. However, results con-
firmed that letrozole treatment effectively reduces estradiol
production in cattle. Finally, the formulation used for the
development of an intravaginal device containing letrozole
impacts on the effect of treatment on ovarian function.
Based on these observations, we hypothesize that a
letrozole-releasing device capable of a more sustained drug
release may delay ovulation even further, while allowing
more than one follicle to develop to a pre-ovulatory size
when treatment is initiated prior to dominant follicle selec-
tion. The effect of estradiol suppression during the pre-
ovulatory stage of follicular development on oocyte compe-
tence and fertility needs to be determined.Conclusions
A sustained-release intravaginal device has potential in the
development of an aromatase inhibitor-based protocol for
control of ovulation for herd synchronization. The en-
hanced effects of letrozole treatment on CL function has
the potential of enhancing fertility by increasing circulating
progesterone concentrations during the first 7 days post-
ovulation in cattle.Competing interests
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